Liver Cirrhoses

7

Review clinical trials related to Liver Cirrhoses. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present. This study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes. The study will compare two groups: 1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG). 2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications). All participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups. The main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment. Participants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes. This study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.

Participants needed: 70
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: The Cleveland ClinicUpdated: Dec 23, 2025Locations: 1
Eligibility criteria

Candidate for general anesthesia. [+9]

Prior bariatric/metabolic surgery (except removed devices ≥ 3 months earlier). [+24]

Status: Recruiting

A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis

DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals. A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability. The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk. Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories. The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.

Participants needed: 600
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Mattias EkstedtUpdated: Dec 19, 2025Locations: 1
Eligibility criteria

Patients with liver cirrhosis, according to clinical practice. Based on criteria... [+2]

Contraindications for MRI (ferrrous material, claustrophobia) [+6]

Status: Recruiting

Developing Viability Index for Machine Perfused Livers

Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collecting biopsies from transplanted livers before and after implantation to correlate metabolite and gene expression with post-transplant function. This data will help develop a viability index for machine perfused livers.

Participants needed: 60
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Nov 3, 2025Locations: 1
Eligibility criteria

Male or female 18-75 years of age. [+1]

Seropositivity for HIV-1.

Status: Recruiting

Liver Disease and Other Systemic Diseases

Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing the data from the Hospital Database of Buddhist Tzu Chi Medical Foundation.

Participants needed: 15,000
Trial details
Age: 18-99Biological sex: AllType: ObservationalSponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationUpdated: Sep 19, 2025Locations: 1
Eligibility criteria

Individuals who visited the gastroenterology clinics of the Tzu Chi Hospitals, B...

Age younger than 18 or older than 99 years

Status: Recruiting

Evaluation of Chronic Liver Disease Condition and Transplant Prognosis Assisted by Eye Biological Parameters

This study investigates the correlation between ocular biological characteristics and overall conditions before and after liver transplantation by collecting ocular biological characteristics. Explore whether it is possible to construct a clinical prediction model for liver transplantation by incorporating ocular biometric features, in order to optimize disease management before and after liver transplantation.

Participants needed: 500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Zhongshan Ophthalmic Center, Sun Yat-sen UniversityUpdated: Jan 1, 2025Locations: 1Duration: 1 Year
Eligibility criteria

Age greater than or equal to 18 years old; [+4]

History of other organ transplant surgeries; [+4]

Status: Recruiting

Non-Invasive Characterization of Focal Liver Lesions in Liver Cirrhosis

This study aims to analyze non-invasive characterization focal liver lesions in patients with liver cirrhosis. The diagnostic accuracy and predictive value of non-invasive methods is studied.

Participants needed: 200
Trial details
Age: 18-99Biological sex: AllType: ObservationalSponsor: University Hospital, BonnUpdated: May 18, 2022Locations: 1
Eligibility criteria

all patients with focal liver lesions and liver cirrhosis

no consent [+1]

Status: Recruiting

Antibiotic Prophylaxis in Patients Undergoing GVO

We design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.

Participants needed: 150
Trial details
Phase: Phase 4Age: 20-85Biological sex: AllType: InterventionalSponsor: Taipei Veterans General Hospital, TaiwanUpdated: Oct 28, 2019Locations: 1
Eligibility criteria

Patients with live cirrhosis and/or hepatoma [+1]

Had a terminal illness of any major organ system,such as heart failure, kindey f... [+2]